诊断和治疗恶性 Priapism 的当前挑战:一个全面的审查
I Wayan Yudiana1, Ronald Sugianto2, Putu Eka Dianti Putri3
1Department of Urology, Universitas Udayana, Prof. Dr. I.G.N.G Ngoerah General Hospital, Faculty of Medicine, Bali, Indonesia.
Urology research & practice
|November 16, 2023
概括
恶性priapism,由于癌症导致的持续勃起,对标准治疗没有反应. 管理侧重于息治疗,以改善生活质量和缓解症状.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 医学科学 医学科学 医学科学
背景情况:
- 恶性 priapism (MP) 是一种罕见的疾病,其特点是阴茎持续勃起,与性刺激无关.
- 它是由影响洞穴鼻腔和静脉的瘤过程引起的.
- 已建立的青症治疗方法对于恶性青症通常是无效的.
研究的目的:
- 审查恶性priapism的治疗格局和结果.
- 为了突出治疗这种疾病的挑战.
主要方法:
- 对有关恶性priapism的现有文献的审查.
- 分析各种治疗方式,包括药物治疗,非手术治疗,手术治疗和放射治疗.
主要成果:
- 标准的嗜食症疗法在恶性嗜食症中表现出有限的有效性.
- 对于MP的治疗方法是多样化的,包括药物治疗,非手术,手术干预和放射治疗.
- 积极的多式疗法 (手术,放射,化疗,向疗法) 的生存率很低.
结论:
- 恶性priapism带来了重大的治疗挑战,生存结果不佳.
- 治疗策略主要是缓解性,旨在提高患者的生活质量和缓解症状.
相关概念视频
Disorders of the Male Reproductive System
426
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
426
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
162
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
162
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
14
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
14
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
176
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
176
Peripheral Artery Disease IV: Nursing Management
11
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
11


